Your session is about to expire
← Back to Search
Semaglutide for Type 1 Diabetes (T1-DISCO Trial)
T1-DISCO Trial Summary
This trial will assess the effects of semaglutide, a medication not approved by the FDA, on people with type 1 diabetes. It may reduce CV disease and kidney disease and improve glucose control and BMI.
T1-DISCO Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowT1-DISCO Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 3 trial • 458 Patients • NCT03015220T1-DISCO Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I or my family have a history of thyroid cancer, MEN2, or pancreatitis.My thyroid condition or blood pressure is not under control despite treatment.My HbA1c is above 9%, or I've recently had diabetic ketoacidosis or been hospitalized.I am on a stable dose of medication for heart or kidney health.I have used diabetes or steroid medications in the last 3 months.I have a serious illness like cancer.You are using an insulin pump or automated insulin delivery system.I am under 30 and have Type 1 Diabetes with antibodies.I am taking medication for mental health that is not a typical antipsychotic.My kidney function, measured by eGFR, is at least 45.Your body mass index (BMI) should be between 20 and 35.I have a heart condition from birth, low blood count, or eye damage due to diabetes.I am between 18 and 49 years old.You are allergic to shellfish or iodine, but this only affects the use of a specific procedure called iohexol clearance.You cannot have an MRI or certain heart procedures, and you are allergic to GLP-1RA.
- Group 1: Placebo
- Group 2: Semaglutide
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What risks have been observed with the use of Semaglutide?
"We at Power rate Semaglutide's safety a 3, given that Phase 3 trials imply the existence of positive efficacy data and multiple layers of evidence for its security."
Does this research experiment have any age restrictions?
"Those eligible to be enrolled in this trial must fit the age criteria of 18-40. There are 223 trials targeting minors and 946 that exclusively focus on adults over 65 years old."
Could I participate in this experiment?
"60 participants aged 18-40 with type 1 diabetes will be admitted to this trial. Additional criteria include having a BMI between 20 and 35 kg/m2, plus the use of insulin pump or automated insulin delivery systems."
Is this exploration still recruiting participants?
"According to clinicaltrials.gov, this medical trial is not actively recruiting any participants at the moment; it was initially published on June 1st 2023 and last edited on April 4th 2023. However, there are still 1287 other trials that require enrolment right now."
Share this study with friends
Copy Link
Messenger